Company: PSTV
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0000950170-25-061028
Chunk: 12

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 12
---
 their employment. No member of the Audit Committee simultaneously serves on the audit committees of more than three (3) public companies, and no member of our Audit Committee has participated in the preparation of the financial statements of Plus at any time during the past three (3) years.

The primary purpose of the Audit Committee is to discharge the responsibilities of our Board with respect to our corporate accounting and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent registered accounting firm. Specific responsibilities of our Audit Committee as provided in the Audit Committee charter include:

reviewing management’s and our independent auditor’s report on their assessment of the effectiveness of internal control over financial reporting as of the end of each fiscal year;

selecting our auditors and reviewing the scope of the annual audit;

resolving any disagreements between management and the auditor regarding financial reporting;

• approving the audit fees and non-audit fees to be paid to our auditors; • reviewing our financial accounting controls with the staff and the auditors; • reviewing and monitoring management’s enterprise risk management assessment, including cyber security; • reviewing and discussing with management and the auditor, our audited financial statements including our disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; • reviewing our earnings press releases as well as financial information and earnings guidance provided to analysts and rating agencies; • reviewing and approving our annual budget; • reviewing all related person transactions which are required to be reported under applicable SEC regulations; and • establishing procedures for the receipt, retention, and treatment of complains received regarding accounting, internal accounting controls or audit matters. Nominating and Corporate Governance Committee Our Nominating and Corporate Governance Committee consists of Mr. Clowes, Dr. Lenk, and Dr. van Es-Johansson, each of whom our Board has determined is “independent” under the Nasdaq listing standards, a non-employee director and free from any relationship that would interfere with the exercise of his or her independent judgment. The Chairperson of our Nominating and Corporate Governance Committee is Dr. van Es-Johansson. Specific responsibilities of our Nominating and Corporate Governance Committee as provided in the Nominating and Corporate Governance Committee charter include, among others: • analyzing the expertise and experience of the Board and ensuring the membership of the Board consists of persons with sufficiently diverse and independent backgrounds; • identifying, recruiting, evaluating and recommending to the Board individuals qualified to become members of the Board; • establishing procedures for the consideration of candidates for the Board recommended by Plus